EFFICACY OF TRABECTEDIN (ET-743) IN PRETREATED PATIENTS WITH ADVANCED/METASTATIC SOFT TISSUE SARCOMA

被引：0
|
作者：
Cianci, G. [1 ]
De Rosa, P. [2 ]
Tonini, G.
Narducci, F. [1 ]
Mentuccia, L. [1 ]
Lolli, I [3 ]
Ercolino, L. [3 ]
Apice, G. [4 ]
D'Aprile, M. [5 ]
Gamucci, T. [1 ]
机构：
[1] ASL Frosinone, Naples, Italy
[2] Med Oncol Cardarelli Hosp, Naples, Italy
[3] Med Oncol Policlin, Bari, Italy
[4] Sarcomas Fdn Pascale, Dept Med Oncol, Naples, Italy
[5] Med Oncol ASL Latina, Latina, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Updated results of Phase II study of trabectedin (ET-743) in pretreated patients with advanced/metastatic soft tissue sarcoma from a single institute
    Mohan, V.
    Chawla, T.
    Alzwahereh, K.
    Jeong, W.
    Kita, K. Y.
    Chua, V. S.
    Kalra, A.
    Rana, G. S.
    Chawla, S. P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Experience of the use of trabectedin (ET-743) in patients with advanced soft tissue sarcoma failing doxorubicin and/or ifosfamide in Korea
    Kim, H.
    Ahn, J.
    Lee, H.
    Kim, T. M.
    Lee, J.
    Park, K.
    Sym, S.
    Choi, Y.
    Lee, K.
    Rha, S. Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer
    Beumer, Jan H.
    Rademaker-Lakhai, Jeany M.
    Rosing, Hilde
    Hillebrand, Michel J. X.
    Bosch, Tessa M.
    Lopez-Lazaro, Luis
    Schellens, Jan H. M.
    Beijnen, Jos H.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (06) : 825 - 837
  • [4] Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer
    Jan H. Beumer
    Jeany M. Rademaker-Lakhai
    Hilde Rosing
    Michel J. X. Hillebrand
    Tessa M. Bosch
    Luis Lopez-Lazaro
    Jan H. M. Schellens
    Jos H. Beijnen
    [J]. Cancer Chemotherapy and Pharmacology, 2007, 59 : 825 - 837
  • [5] Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma
    Schoffski, Patrick
    Dumez, Herlinde
    Wolter, Pascal
    Stefan, Cristiana
    Wozniak, Agnieszka
    Jimeno, Jose
    Van Oosterom, Allan T.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (09) : 1609 - 1618
  • [6] DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743).
    Schöffski, P.
    Casali, P. G.
    Taron, M.
    Van Oosterom, A. T.
    Judson, I. R.
    Grosso, F.
    Blay, J. Y.
    Maki, R. G.
    Tercero, J. C.
    Jimeno, J. M.
    Rosell, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 525S - 525S
  • [7] Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma
    Tewari, Devansu
    Saffari, Bahman
    Cowan, Carol
    Wallick, Anita C.
    Koontz, M. Zach
    Monk, Bradley J.
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 102 (03) : 421 - 424
  • [8] Trabectedin for the treatment of advanced metastatic soft tissue sarcoma
    Simpson, E. L.
    Rafia, R.
    Stevenson, M. D.
    Papaioannou, D.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 63 - 67
  • [9] Impact of Yondeli™ (trabectedin, ET-743) in the natural history of patients (pts) with pretreated advanced soft tissue sarcomas (PASTS):: Long term follow-up results.
    Lecesne, A
    Demetri, G
    Misset, JL
    Blay, J
    Judson, I
    Yovine, A
    Van Oosterom, A
    Radford, J
    Verweij, J
    Maki, R
    Brain, E
    Herait, P
    Izquierdo, MA
    Gómez, J
    Nieto, A
    Saro, J
    Jimeno, J
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6076S - 6076S
  • [10] Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer
    J. H. Beumer
    J. M. Rademaker-Lakhai
    H. Rosing
    L. Lopez-Lazaro
    J. H. Beijnen
    J. H. M. Schellens
    [J]. Investigational New Drugs, 2005, 23 : 429 - 436
12345